NLRP3 and neoplasm: Similarly, tumor size on Day 49 in the NLRP3/α-PD-1 + α-CTLA-4 group was significantly smaller compared to the NLRP3 agonist alone or the ICIs alone group (p = 0.009 and 0.029, respectively).